South Africa will begin providing lenacapavir on June 5 after delays tied to postimportation testing, while Uganda has launched rollout of the twice-yearly HIV prevention injection in Lira.
Trump secured agreements with 16 pharmaceutical companies tied to TrumpRx.gov, including most-favoured-nation pricing and direct-to-patient discounts. Several companies disclosed price cuts for obesity, diabetes, insulin and other medicines.
Three advances in TB diagnostics: a portable $300 device delivering results in 30 minutes, a Quick DNA kit detecting drug resistance in 5 minutes, and an ultrasensitive test finding TB DNA in 12-16% of hospitalized US patients.
Pitt received $669.7 million in NIH funding in 2025 to rank No. 7 nationally. Penn Nursing received $17.9 million, ranking first among U.S. nursing schools.
FDA grants Priority Review for Gilead's bictegravir/lenacapavir single-tablet HIV regimen. The NDA is supported by ARTISTRY-1 and ARTISTRY-2 trials showing noninferiority. A PDUFA target date of August 27, 2026 has been set.
A cost-effectiveness analysis found home-based anal cancer screening increased participation versus clinic-based screening among sexual and gender minority individuals. The approach remained investigational because the FDA has not approved self-sampling for anal cancer screening.
Lenacapavir was launched in Zimbabwe in February 2026 as Kenya became the fourth African country to start administering the twice-yearly HIV prevention injection. The rollout follows launches in Eswatini and Zambia in December 2025, five months after US FDA approval.
Tennessee has implemented comprehensive pharmacist scope-of-practice expansion allowing independent prescribing, testing, and treatment for select conditions. The legislation enables pharmacists to prescribe medications including antivirals, contraceptives, and naloxone without collaborative agreements. This expansion aims to improve healthcare access, particularly in rural areas with provider shortages.
Big drug companies said Trump administration pricing deals had little to no noticeable impact on earnings, though details remain confidential. Novo Nordisk and Eli Lilly described bigger effects tied to lower GLP-1 cash-pay prices and expanded Medicare coverage.
The National Institute of Allergy and Infectious Diseases has been instructed to remove "biodefense" and "pandemic preparedness" language from its website, signaling a major shift away from these research priorities. NIH leadership says the institute will now focus on current infectious diseases and basic immunology rather than predicting future threats. Public health experts warn this could leave the U.S. less prepared for future health emergencies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07589985 |
Hep Mec Cohort in Zambia |
RECRUITING | |
| NCT07579247 |
Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07574619 |
Improving Choice And Use Of Biomedical HIV Prevention For Women In Uganda: A Couples-based Approach |
RECRUITING | NA |
| NCT07569029 |
A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies |
NOT_YET_RECRUITING | PHASE1 |
| NCT07564193 |
The Coach Mpilo Study: Evaluation of a Peer-led Intervention to Promote Engagement in HIV Care for Men Living With HIV |
NOT_YET_RECRUITING | NA |
| NCT07561658 |
TelePharm PrEP/PEP |
NOT_YET_RECRUITING | NA |
| NCT07553949 |
Leveraging Pharmacy Technicians to Advance the Reach of Modern Antiretroviral Therapy (PHARM ART) in Community Clinics |
NOT_YET_RECRUITING | NA |
| NCT07528573 |
HIV Prevention and Care Engagement in Nepal |
COMPLETED | NA |
| NCT07516691 |
Evaluation of a New Strategy to Approach the Transgender Sex Worker Populations and Their Clients for Access to a Preventive Sexual Health System Through the ORTIF Digital Teleconsultation Solution |
NOT_YET_RECRUITING | |
| NCT07510048 |
Combatting HIV Or Other STIs Early (CHOOSE) |
NOT_YET_RECRUITING | PHASE2 |
